Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rituximab-ADNAB (Mayo Clinic)
- Development stage
- Preclinical
- Lead developer
- Sorrento Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Subcutaneous
01
Overview
Rituximab-ADNAB is a non-covalent antibody-drug conjugate (ADC) developed by Mayo Clinic and exclusively licensed to Sorrento Therapeutics through its subsidiary ADNAB, Inc. This innovative platform combines the tumor-targeting monoclonal antibody rituximab with nanoparticle albumin-bound paclitaxel. The drug is designed to treat hematological malignancies, solid tumors, and potentially autoimmune diseases by specifically delivering a cytotoxic payload to target cells. Two ADNAB candidates, including Rituximab-ADNAB, were already in investigator-initiated human trials at the time of the announcement.
- Other names
- nab-paclitaxel nanoparticles non-covalently coated with rituximab
02
Targets
CD20 (B-lymphocyte antigen CD20)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Rituximab-ADNAB (Mayo Clinic).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rituximab-ADNAB (Mayo Clinic).